Bharat Biotech has launched India’s only integrated Cell and Gene Therapy Facility and Viral Vector Production Unit at Genome Valley, Hyderabad. The expansion moves the company beyond vaccines into cutting-edge regenerative and personalized therapies, offering new hope for millions of patients.
Transforming Treatment with Cell and Gene Therapies
The new facility will drive innovation in gene and cell therapies, tackling challenges like targeted gene expression, immune modulation, and cell survival. Bharat Biotech aims to boost immune responses against cancer and safely deliver therapeutic proteins for genetic disorders like hemophilia.
A State-of-the-Art Facility for Global Impact
Spanning 50,000 square feet, this advanced CGT facility represents a crucial step in Bharat Biotech’s mission to provide life-saving treatments for unmet clinical needs. The company will primarily focus on critical conditions, such as hematological malignancies and inherited blood disorders. As a result, it aims to strengthen its role in global healthcare while simultaneously enhancing patient outcomes.
Expertise in Precision Medicine
Dr. Krishna Ella, Bharat Biotech’s Executive Chairman, emphasized the complexity and advanced nature of gene and cell therapies.
Ella said, “These therapies require precise genetic manipulation and specialized manufacturing capabilities. With our extensive experience in viral vaccine production, Bharat Biotech is uniquely positioned to master these complexities and deliver human-grade vectors for clinical trials”.
Advancing the Fight Against Rare Diseases
Bharat Biotech is using its expertise in viral vaccine manufacturing to expand gene and cell therapy production for clinical use. According to newsmeter.in, this move strengthens India’s role in treating rare diseases and advancing personalized medicine.
